Table 1.

Summary of outcomes evaluated in Cohorts 1 and 2.

Cohort 1	Control	Glibenclamide	p value
neuro score	6 [0– 6]	7 [6–8]	0.025
mortality	5 (33%)	2 (15%)	0.400
direct stroke volume	483±60	323±42	<0.001
indirect stroke volume	72±8%	53±7%	<0.001
swelling, %	28±7%	10±4%	<0.001
MMP-9, 48 hr, (ng/mL)	11.4±2.5	8.5±3.0	0.042
glucose, 48 hr, (mg/dL)	160±25	131±24	0.014
HT densitometry	1.15±0.16	0.94±0.05	<0.001
Hemorrhage volume, μL	6.2±4.6	2.7±1.5	0.011
HT categories			<0.001
None	1	8
HI1	1	4
HI2	9	1
PH1	4	0
Cohort 2	Control	Glibenclamide	p value
neuro score	7 [6–8]	8 [8–10]	0.021
mortality	3 (25%)	2 (17%)	0.999
direct stroke volume, mm3	335±161	183±76	0.028
indirect stroke volume, %	45±11%	36±11%	0.107
swelling, %	20±13%	5±5.5%	0.003
MMP-9, 48 hr, (ng/mL)	41.3±19.6	31.6±6.7	0.209
glucose, 48 hr, (mg/dL)	191±35	155±19	0.012
HT categories			<0.01
None	1	8
HI1	1	2
HI2	5	0
PH1	2	0